This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With significant progress made in researchers’ understanding of dermatological diseases, a pathway has been made for the development of targeted vaccines, according to data published in Vaccines. 5 Throughout the past 10 years, development of vaccines for preventing skin diseases has made significant progress.
While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. | By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday.
The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.
The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.
Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.
Now, the WHO’s aggressive goal to “ end HIV/AIDS ” by 2030 could be hampered by dramatic reductions in U.S. A long-time leader in vaccines, the U.K. pharma is facing potential headwinds as the FDA’s attitude toward immunizations shifts under new leadership. While Enhertu pulled in about $3.8
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Addressing pharmacy deserts and enhancing interdisciplinary collaboration, especially with social workers, are crucial for improving health care access.
How will RFK Jr’s American dream for vaccines play out? Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic.
A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5
CAR T-cell therapies dominate the genetically modified space, targeting cancer in 97% of cases, while non-genetically modified therapies focus on regenerative medicine. Technological advances, such as CRISPR-Cas9 and in vivo cell engineering, are addressing challenges like short-term cell persistence and antigen escape.
2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.
Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.
Bleeding after circumcision Bleeding after having shots, such as vaccinations. by 2030 at a CAGR of 6.9% Symptoms:1 Prolonged oozing after injuries, tooth extractions or surgery Hematoma Bruising Bleeding into the joints, mouth and gums Bleeding of the mouth and gums, and bleeding that is hard to stop after losing a tooth.
Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.
billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab.
million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). million (approximately US$1.99 The company said in June 2025 that it raised €11.25 million (US$12.9
The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.
On December 20, 2022, the World Health Organization (WHO) updated its recommendations for cervical cancer vaccines in a bid to boost vaccination coverage. Several cervical cancer vaccines are currently approved, including Merck’s nonavalent vaccine Gardasil 9 and GSK’s bivalent vaccine Cervarix.
READ MORE: Q&A: Myths, Misinformation Surrounding Hepatitis Vaccines The study cohort included 283 patients 12 years of age or older with an acute HCV Infection who were treatment-naïve. Passport to Protection: Best Practices for Travel Vaccines in the Pharmacy Setting Gretchen K.
million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. A steady increase in CVD-related deaths resulted in approximately 18.6 1 CVDs are disorders affecting the heart and blood vessels.
WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.
The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. These hubs have more than 30 potential vaccines and medicines targeting 13 high-burden infectious diseases.
The former blockbuster – first approved back in 1998 – is still making solid sales despite losing patent protection, with AZ booking $410 million from the drug last year, but are expected to drop sharply once Beyfortus and vaccines for RSV prevention reach the market. Both vaccines are also being tested in older adults.
The costs are expected to increase to $246 billion by the year 2030. Immunotherapy: This treatment stimulates the immune system’s natural defense to recognize and kill cancer cells. (ALA , 2022) There is a higher survival rate of 56% if the tumor is still in the lungs and has not spread to other organs. ( in 2023. (
It will also limit the annual increases in Part D premiums for the years 2024 to 2030, plus make other changes to Part D benefits. Cost sharing for adult vaccines covered by Medicare Part D will be eliminated In 2020, more than 4 million Medicare beneficiaries received a vaccine covered under Part D, including 3.6
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content